KRAS and colorectal cancer: Vemurafenib, a BRAF inhibitor, reduced pS-EphA2 in cells harbouring BRAF mutation, but rather increased pS-EphA2 in NRAS-mutated SK-MEL-2 cells (Fig. 6a) as well as in KRAS-mutated DLD-1 human colorectal cancer cells (Fig. 6b).